Drug Trial Radar · NCT06097273
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,061
Actual
Start
Oct 19, 2023
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Oct 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Conditions
- SARS-CoV-2
- Influenza
Interventions
mRNA-1083Biological
Suspension for injection
PlaceboBiological
0.9% sodium chloride suspension for injection
Influenza VaccineBiological
Commercially available formulation (Suspension for injection \[pre-filled syringe\])
COVID-19 VaccineBiological
Commercially available formulation (Suspension for injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
- GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)Time frame: Day 29
- Influenza: Percentage of Participants With Seroconversion, as Measured by HAI AssayTime frame: Baseline to Day 29
- SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNATime frame: Baseline to Day 29
- Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to 7 days after study injection
- Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Up to 28 days after study injection
- Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to DiscontinuationTime frame: Day 1 through Day 181
Locations
146 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group-409 E 10th St
Anniston, Alabama
Accel Research Site - Achieve - Birmingham
Birmingham, Alabama
Cullman Clinical Trials
Cullman, Alabama
Desert Clinical Research - CCT - PPDS
Mesa, Arizona
Foothills Research Center - CCT - PPDS
Phoenix, Arizona
Headlands Research - Scottsdale - PPDS
Scottsdale, Arizona
Scottsdale Clinical Trials
Scottsdale, Arizona
Fiel Family & Sports Medicine - PC - CCT - PPDS
Tempe, Arizona
AES - DRS - Synexus Clinical Research US, Inc. - Cerritos
Cerritos, California
Long Beach Research Institute, LLC
Long Beach, California
CenExel Apex (CNS) - Los Alamitos - PPDS
Los Alamitos, California
Central Valley Research, LLC
Modesto, California
Carbon Health- NoHo West Urgent Care and Primary Care
North Hollywood, California
Empire Clinical Research
Pomona, California
Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS
Riverside, California
Clinical Innovations Trials - Riverside - CenExel - PPDS
Riverside, California
Peninsula Research Associates - Headlands - PPDS
Rolling Hills Estates, California
Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS
San Diego, California
AES - DRS - Synexus Clinical Research US, Inc. - Vista
Vista, California
Tekton Research - Fort Collins - PPDS
Fort Collins, Colorado
Tekton Research - Longmont - PPDS
Longmont, Colorado
Stamford Therapeutics Consortium - ERN - PPDS
Stamford, Connecticut
Chase Medical Research LLC - Waterbury
Waterbury, Connecticut
Revival Research Corporation
Doral, Florida
Indago Research and Health Center
Hialeah, Florida
CenExel RCA - Hollywood
Hollywood, Florida
Nature Coast Clinical Research
Inverness, Florida
Jacksonville Center For Clinical Research
Jacksonville, Florida
Health Awareness - Jupiter - ERN - ERN
Jupiter, Florida
Accel Research Sites - Saint Petersburg - Largo - ERN - PPDS
Largo, Florida
Flourish Research - Leesburg - PPDS
Leesburg, Florida
Accel Research Sites - Maitland
Maitland, Florida
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida
Suncoast Research Group LLC - Flourish - PPDS
Miami, Florida
St. Johns Center for Clinical Research - ERN - PPDS
Saint Augustine, Florida
ForCare Clinical Research - CenExel FCR - PPDS
Tampa, Florida
AES - DRS - Synexus Clinical Research US, Inc. - Atlanta
Atlanta, Georgia
DelRicht Research, LLC - Springer Wellness & Restorative - Atlanta - PPDS
Atlanta, Georgia
iResearch Atlanta - CenExel - PPDS
Decatur, Georgia
Javara, Inc./Privia Medical Group Georgia, LLC - Fayetteville - Javara - PPDS
Fayetteville, Georgia
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.